Swing Therapeutics

Swing Therapeutics is a digital therapeutics (DTx) startup focused on developing prescription-based treatments for autoimmune conditions and chronic overlapping pain conditions. The company incorporates cognitive behavioral therapy (CBT), including acceptance and commitment therapy, when developing its app-based treatments.

Its lead product for treating patients with fibromyalgia, a chronic pain condition, was in Phase 3 of its PROSPER-FM clinical trial as of June 2022. The DTx program, which received FDA Breakthrough Device Designation in August 2021, includes CBT-based lessons and interactive exercises to help manage chronic pain, a digital symptom tracker, as well as access to fibromyalgia and general health education. The clinically validated program was exclusively licensed from the University of Manitoba. Swing also has a second clinical trial, REACT-FM, underway, consisting of a single-arm trial with more than 100 patients enrolled as of June 2022.

Funding and Financials

In June 2022, the firm raised USD 10.3 million in a Series A funding round led by Jazz Venture Partners, which was allocated toward supporting its PROSPER-FM clinical trial and for the introduction of an affiliated telehealth feature.